#treatmentresistantdepressiontrd

  1. COMPASS Pathways Q3 2023 Results: Cash Injection To Sustain Phase 3 Psilocybin Program

    By Lara Goldstein COMPASS Pathways plc (NASDAQ: CMPS ), the London-headquartered psychedelics biotech company reported financial results for the third quarter 2023 ended September 30 , showing: Cash and cash equivalents of $248.0 million as of Sept. 30, 67% more than that held on las